• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Parkinson's disease drug can cause corneal damage

Article

Parkinson's disease patients taking the drug amantadine are at risk for damage to the corneal endothelium and resulting impaired vision, which can become more pronounced the longer the drug is used, according to research.

Ophthalmology. 2010;117:1214-1219. [June 2010]

Parkinson's disease patients taking the drug amantadine are at risk for damage to the corneal endothelium and resulting impaired vision, which can become more pronounced the longer the drug is used, according to researchers from Seoul National University in South Korea. They compared the endothelial changes in the corneas of 169 subjects with Parkinson's disease taking oral amantadine with a control group of 169 age- and gender-matched healthy subjects not taking the medication. The researchers found that, compared to the control group, the subjects taking amantadine had significantly lower endothelial cell density, a lower hexagonality, as well as a greater coefficient of variation. The reduction in endothelial cell density increased when the duration and cumulative dose of amantadine increased.

Related Videos
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health
© National Institute for Occupational Safety and Health